Summary
Didemnin B (NSC 325319), a cyclic depsipeptide isolated from a Carribean sea tunicate, exhibited potent antitumor activity in preclinical studies. After determining the maximum tolerated dose in our previous phase I/II trial, we conducted a phase II study of this drug in patients with previously treated small cell lung cancer; the starting dose was 6.3 mg/m2 intravenously over 30 min every 28 days. The major side effects were in the neuromuscular system and included severe muscle weakness, myopathy and/or myotonia by electromyography, and elevation of creatine phosphokinase and aldolase levels. We also observed modest increases in bilirubin and alkaline phosphatase levels. There were minimal hematologic toxic effects. No response was observed among 15 evaluable patients, leading us to conclude that didemnin B was toxic but inactive in patients with previously treated small cell lung cancer at the stated dose and schedule. A review of the literature revealed no significant antitumor activity in cancers of the colon, breast, ovaries, cervix, or lung (non-small cell) or in renal cell carcinoma. Further clinical trials for didemnin B may not be warranted at the stated dose and schedule.
Similar content being viewed by others
References
Rhineart KL Jr, Grover JB, Hughes RG Jr, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933–955, 1981
Houssain MB, Van De D, Weinheimer AJ: Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide. Proc Natl Acad Sci USA 85:4118–4122, 1988
Jiang TL, Liu RH, Salmon SE: Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11:1–4, 1983
Li LH, Timmins LG, Wallace TL, Krueger WC, Prairie MD, Im WB: Mechanism of action of didemnin B, a depsipeptide from the sea. Cancer Lett 23:279–288, 1984
Crampton SL, Adams EG, Kuentzel SL, Li LH, Badiner G, Bhuyan BK: Biochemical and cellular effects of didemnin A and B. Cancer Res 44:1795–1801, 1984
Dorr FA, Kuhn J, Phillips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 2:1699–1706, 1988
Tong WP, Webster LK, Hartshorn JN, Stewart JA, McCormack JJ: Chronographic assay for didemnin B and application to pharmacological studies. Proc Am Assoc Cancer Res 27:A281, 1986
Abbruzzese J, Ajani J, Blackburn R, Faintuch J, Patt Y, Levin B: Phase II study of didemnin B in advanced colorectal cancer. Proc Am Assoc Cancer Res 29:A805, 1988 (abstract)
Shin DM, Holoye PY, Murphy WK, Forman A, Papasozomemus SC, Hong WK, Raber M: Phase I/II clinical trial of didemnin B in non-small cell lung cancer: neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol 29:145–149, 1991
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Forman AD, Shin DM, Jackson R: Myotonia in patients treated for cancer with didemnin B. Muscle & Nerve 15:515–517, 1992
Kwiecinski H: Myotonia induced with clofibrate in rats. J Neurol 219:207–116, 1978
Al-Rajeh S, Vasudeva J, Olson WH: Effect of Diltiazem on 2,4-D-(dichlorophenoxy) aceti acid induced myotonia on rats. Muscle & Nerve 12:470–472, 1989
Barchi R: Myotonia. Neuro Clin 6:473–484, 1988
Paul T, Katiyar BC, Misra S, Pant GC: Carcinomatous neuromuscular syndromes. A clinical and quantitative electrophysiologic study. Brain 101:53–63, 1978
Teravainen H, Larsen A: Some features of the neuromuscular complications of pulmonary carcinoma. Ann Neurol 2:495–502, 1977
Rossof AH, Rowland K, Khandekar J, Kilton L, Benson AB, III Blough R, Howe H: Phase II trial of didemnin B in previously untreated patients with measurable meta-static colorectal carcinoma. Proc Am Soc Clin Oncol 8:A439, 1989 (abstract)
Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL: Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs 10:211–213, 1992
Benvenuto JA, Newman RA, Bignami GS, Raybould TJG, Raber MN, Espara L, Walters RS: Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs 10:113–117, 1992
Cain JM, Liu PY, Alberts DE, Gallion HH, Laufman L, O'Sullivan J, Weiss G, Bickers JN: Phase II trial of didemnin B in advanced epithelial ovarian cancer, a Southwest Oncology Group study. Invest New Drugs 10:23–24, 1992
Melfetano JH, Blessing JA, Jacobs AJ: A phase II trial of didemnin B (NSC #325319) in patients with previously treated epithelial ovarian cancer: a Gynecologic Oncology Group Study. Am J Clin Oncol 16:47–49, 1993
Jacobs AJ, Blessing JA, Munoz A: A phase II trial of didemnin B (NSC #325319) in advanced and recurrent cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 44:268–270, 1992
Taylor SA, Goodman P, Crawford ED, Stuckey WJ, Stephens RL, Gaynor ER: Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. Invest New Drugs 10:55–56, 1992
Motzer R, Scher H, Bajorin D, Sternberg C, Bosl GJ: Phase II trial of didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs 8:391–392, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shin, D.M., Holoye, P.Y., Forman, A. et al. Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Invest New Drugs 12, 243–249 (1994). https://doi.org/10.1007/BF00873966
Issue Date:
DOI: https://doi.org/10.1007/BF00873966